The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort

Sponsor
St. Justine's Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03356262
Collaborator
(none)
630
227.2

Study Details

Study Description

Brief Summary

The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort study is a unique and comprehensive longitudinal study of 630 Caucasian children and their parents that was designed to investigate the natural history and determinants of childhood obesity and its cardiometabolic consequences.

Detailed Description

The QUALITY Cohort is funded by the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, as well as the Fonds de la recherche en santé du Québec. The multidisciplinary study team comprises over 20 researchers with a wide variety of relevant expertise as well as research fellows, students and staff (www.etudequalitystudy.ca).

The specific objectives of QUALITY are: 1) To increase understanding of the natural history of excess weight and its associated cardiometabolic consequences (dyslipidemia, hyperinsulinemia, dysglycemia, inflammation, elevated blood pressure, sympathetic overactivity) in youth at risk for the development of obesity; 2) To investigate the relative importance of the genetic, biological, environmental and psychosocial determinants of excess weight and its associated cardiometabolic consequences. Determinants of particular interest include social factors (socio-economic status, family composition, built environment), behavioural factors (eating behaviour, physical activity, smoking, sleep, stress), biological factors (adverse fetal environment, body fat distribution, growth trajectory, aerobic fitness), metabolic factors (insulin sensitivity, adipocytokines), and genetic/familial factors (family history, parental characteristics, gene variations); 3) To examine the relation between obesity, cardiometabolic complications, and subclinical markers of atherosclerosis; and 4) To examine whether obesity and its associated risk factor are related to children's oral health.

The QUALITY Cohort used a school-based sampling strategy to identify potential participants. About 400 000 recruitment flyers were distributed over three consecutive years to parents of children in Grades 2 to 5, in 1040 primary schools (89% of schools approached) including 44 private schools situated within 75 km of Montreal, Quebec City and Sherbrooke in the province of Quebec, Canada. Families interested in participating were invited to contact the research coordinator for additional information, to confirm eligibility, and to set an appointment with the research team; 1320 of 3350 families who contacted the coordinator met the inclusion criteria. Six hundred and thirty families agreed to participate and completed the baseline evaluation.

Study Design

Study Type:
Observational
Actual Enrollment :
630 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort
Actual Study Start Date :
Jul 25, 2005
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Body mass index (BMI) [Through study completion, 13 - 14 years post baseline]

    Weight (kg) and height (m) will be combined to report BMI in kg/m^2 and transformed to z-scores using WHO standards

Secondary Outcome Measures

  1. Waist circumference [Through study completion, 13 - 14 years post baseline]

    Measured in centimeters, midway between the last floating rib and the iliac crest

  2. % body fat mass [Through study completion, 13 - 14 years post baseline]

    Measured using dual energy x-ray absorptiometry and combined as total body fat mass in kg / total body mass in kg * 100

  3. Impaired fasting glucose [Through study completion, 13 - 14 years post baseline]

    Measured from a blood sample collected using venipuncture following a 12-hour overnight fast. Plasma glucose concentrations were computed on the Beckman Coulter Synchron LX20 automat using the glucose oxidase method. Analyses were performed in batches at the Centre Hospitalier Universitaire Sainte-Justine Clinical Biochemistry laboratory twice monthly. Considered as impaired fasting blood glucose if greater or equal to 5.6 mmol/L.

  4. Impaired glucose tolerance [Through study completion, 13 - 14 years post baseline]

    Participants underwent a 2-hour oral glucose tolerance test (OGTT) after a 12-hour overnight fast. Blood samples were collected at 30-, 60-, 90-, and 120-minute intervals after an oral glucose dose of 1.75 g/kg of body weight (maximum 75 g). Plasma glucose concentrations were computed on the Beckman Coulter Synchron LX20 automat using the glucose oxidase method. Analyses were performed in batches at the Centre Hospitalier Universitaire Sainte-Justine Clinical Biochemistry laboratory twice monthly. Considered as impaired glucose tolerence blood glucose at 2hrs of the OGTT greater or equal to 7.8 mmol/L.

  5. Type 2 diabetes [Through study completion, 13 - 14 years post baseline]

    Type 2 diabetes was diagnosed according to recognized criteria from the Canadian Diabetes Association (Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013;37(suppl 1):S1-S212.)

  6. Hypertension (systolic) [Through study completion, 13 - 14 years post baseline]

    Systolic and diastolic blood pressures (SBP and DBP, respectively) were measured using an appropriately sized arm cuff and an automated oscillometric blood pressure monitor doing 5 repeat measures at 1 min intervals (Dinamap model CR9340). Participants were seated and had to rest for 5 minutes prior to the measurement. The average of the last three measures of SBP and DBP was used in the analyses. These were then transformed to age-, sex-, and height-specific Z-scores according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Considered hypertensive if SBP > 95th percentile for age, sex, and height.

  7. Hypertension (diastolic) [Through study completion, 13 - 14 years post baseline]

    Systolic and diastolic blood pressures (SBP and DBP, respectively) were measured using an appropriately sized arm cuff and an automated oscillometric blood pressure monitor doing 5 repeat measures at 1 min intervals (Dinamap model CR9340). Participants were seated and had to rest for 5 minutes prior to the measurement. The average of the last three measures of SBP and DBP was used in the analyses. These were then transformed to age-, sex-, and height-specific Z-scores according to The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Considered hypertensive if DBP > 95th percentile for age, sex, and height.

  8. Dyslipidemia [Through study completion, 13 - 14 years post baseline]

    Blood samples were obtained by venipuncture after a 12 hour overnight fast. Lipids (high density lipoprotein (HDL) cholesterol and triglycerides) were measured on a Synchron LX®20 analyzer, with Beckman Instruments reagents, by the Department of Clinical Biochemistry at CHU Sainte-Justine, according to the recommendations of the International Federation of Clinical Chemistry. Low density lipoprotein (LDL) cholesterol was calculated based on the Friedewald equation. Dyslipedimia was defided according to published guidelines (Pediatrics. 2011 Dec; 128(Suppl 5): S213-S256.)

Eligibility Criteria

Criteria

Ages Eligible for Study:
8 Years to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Children aged 8-10 years at baseline;

  • Caucasian of Western European ancestry;

  • At least one obese biological parent (i.e., body mass index (BMI) ≥30 kg/m2 or waist circumference >102 cm in men and >88 cm in women, based on self-reported measurements of height, weight and waist circumference)

  • Both biological parents available to participate in the baseline assessment.

Exclusion Criteria:
  • Children with a previous diagnosis of Type 1 or 2 diabetes;

  • Children with a previous diagnosis of a serious illness, psychological condition, or cognitive disorder which hindered participation in some or all of the study components;

  • Children treated with anti-hypertensive medication or steroids (except if administered topically or through inhalation);

  • Children following a very restricted diet (< 600 kcal/day);

  • Mother pregnant or breastfeeding at the baseline evaluation;

  • Family with pending plans to move out of the province of Quebec (Canada).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • St. Justine's Hospital

Investigators

  • Principal Investigator: Melanie Henderson, MD, PhD, Université de Montréal

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Melanie Henderson, Clinical assistant professor, St. Justine's Hospital
ClinicalTrials.gov Identifier:
NCT03356262
Other Study ID Numbers:
  • QUALITY
First Posted:
Nov 29, 2017
Last Update Posted:
Oct 22, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Melanie Henderson, Clinical assistant professor, St. Justine's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 22, 2020